Related Experiment Videos
Subclinical hyperthyroidism and cardiovascular risk: recommendations for treatment
Christopher Palmeiro1, Maria I Davila, Mallika Bhat
1From the *Department of Medicine, Division of Endocrinology, New York Medical College, Westchester Medical Center, Valhalla, NY; and †Department of Medicine, Division of Cardiology, New York Medical College, Westchester Medical Center, Valhalla, NY.
Cardiology in Review
|April 9, 2013
Summary
Subclinical hyperthyroidism (SHy) involves low thyroid-stimulating hormone (TSH) with normal thyroid hormones. While cardiovascular risks are debated, evidence suggests increased atrial fibrillation and mortality, particularly in older adults with suppressed TSH.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Gerontology
Background:
- Subclinical hyperthyroidism (SHy) is characterized by suppressed thyroid-stimulating hormone (TSH) with normal free thyroxine (T4) and triiodothyronine (T3) levels.
- Cardiovascular risks associated with overt hyperthyroidism are established, but the impact of SHy remains controversial.
- Existing research indicates a potential link between SHy and adverse cardiovascular events, particularly atrial fibrillation in older populations.
Purpose of the Study:
- To review the current understanding of cardiovascular risks associated with subclinical hyperthyroidism.
- To evaluate the evidence regarding the association between SHy and mortality.
- To discuss the uncertainties surrounding the long-term effects of SHy in different age groups and TSH suppression levels.
Main Methods:
- Review of multiple studies and meta-analyses examining subclinical hyperthyroidism.
- Analysis of data focusing on cardiovascular outcomes, including atrial fibrillation and mortality.
- Consideration of factors such as patient age and degree of TSH suppression.
Main Results:
- Multiple studies show an increased risk of atrial fibrillation in individuals with SHy, especially older adults with TSH levels <0.1 mU/L.
- Recent meta-analyses suggest a modest increase in all-cause and cardiovascular mortality associated with SHy, escalating with age and lower TSH levels.
- The long-term cardiovascular and osteoporotic fracture risks in younger adults and those with mildly suppressed TSH remain uncertain.
Conclusions:
- Treatment guidelines for SHy are individualized, considering age, TSH suppression severity, symptoms, and overall cardiovascular and fracture risks.
- Further research is needed to clarify the long-term consequences of SHy, particularly in younger populations and those with less severe TSH suppression.
- The evidence suggests a need for careful risk assessment and management in patients diagnosed with subclinical hyperthyroidism.
Related Concept Videos
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...